Dr. Ravi K. Sajja is a board certified (Diplomate of the American Board of Toxicology) toxicologist with more than 10 years of experience in the field of pharmaceutical toxicology and regulatory toxicology. He has more than 6 years of experience in regulatory toxicology and has authored and reviewed toxicological risk assessments for a broad range of medical devices (including combination products) and personal care products. His specialties and interests are in small-molecule pharmaceutical discovery toxicology, toxicogenomics, quantitative toxicological risk assessment of extractable & leachable compounds, computational/predictive toxicology models, and regulatory interactions.
Ravi received his Ph.D. in pharmaceutical sciences (neuropharmacology track) in 2012 from the Department of Pharmaceutical Sciences at South Dakota State University. He later pursued postdoctoral research training at Texas Tech University Health Sciences Center, Amarillo in Texas. During his postdoctoral fellowship, he led research focused on the design and development of advanced in vitro models (microphysiological models) of human blood-brain barrier and in vivo imaging models to investigate the molecular mechanisms of drug- and chemical-induced neurovascular toxicity. In collaboration with toxicology and pharmacology leaders, including clinicians from academia and FDA, Dr. Sajja used toxicogenomics, brain-on-chip models, and clinical biomarker approaches to investigate and identify the molecular markers of neuro(vascular)toxicity and studied transporter mediated drug-drug interactions and altered brain pharmacokinetics of anti-cancer drugs. He has authored and co-authored over 25 scientific publications in highly regarded journals in the field and presented his research findings at various national and international conferences, such as Society of Toxicology annual meeting. He also served as ad hoc reviewer for various scientific journals publishing pharmacology and toxicology research and as an abstract reviewer for professional organizations such as AAPS.
For nearly 4 years at Nelson Laboratories Ravi has conducted toxicological risk assessments for a broad range of medical devices and helped to address regulatory deficiencies for device submissions. He has strong familiarity with various guidance documents on toxicology risk assessment procedures and also has extensive experience in leveraging computational toxicological models in performing risk assessments.
